Objective. To update a past systematic review on whether Medicare Part D changed drug utilization and out-of-pocket (OOP) costs overall and within subpopulations, and to identify evidence gaps. Data Sources/Study Setting. Published and gray literature from 2010 to 2015 meeting prespecified screening criteria, including having a comparison group, and utilization or OOP cost outcomes. Study Design. We conducted a systematic literature review with a quality assessment. Data Collection/Extraction Methods. For each study, we extracted information on study design, data sources, analytic methods, outcomes, and limitations. Because outcome measures vary across studies, we did a qualitative synthesis rather than meta-analysis. Principal Findings. Sixty-five studies met screening criteria. Overall, Medicare Part D enrollees have increased drug utilization and decreased OOP costs, but coverage gaps limit the program's impact. Beneficiaries whose insurance becomes more generous after enrollment had disproportionately increased drug utilization and decreased OOP costs. Outcomes among dual-eligibles were mixed. Conclusions. There is strong evidence on how Medicare Part D and the donut hole coverage gap affect utilization and OOP costs, but weak evidence on how effects vary among dual-eligibles or across diseases. Findings suggest that the Affordable Care Act's provisions to expand coverage and reduce the donut hole should improve patient outcomes.
plans and complicated coordination of benefits between Medicare, Medicaid, and Part D plans (The Henry J. Kaiser Family Foundation 2006) . A previous 2010 systematic review found that Medicare Part D increased drug utilization and decreased OOP costs; but the donut hole unfavorably impacted drug utilization, medication adherence, and OOP costs (Polinski et al. 2010 ). There were no observed changes in dual-eligibles' behaviors, whereas vulnerable populations such as those with HIVor mental illness experienced difficulties during the transition period. A major limitation of this previous review is the short time frame. Since Medicare Part D was implemented in January 2006, researchers were unable to evaluate long-term policy effects, including the donut hole. Second, existing studies did not specify the impact on dual-eligibles. We updated the previous systematic review (Polinski et al. 2010) , focusing on long-term impacts and heterogeneous effects on subpopulations including dual enrollees and with different health conditions.
METHODS
We followed the Institute of Medicine's systematic review guidelines (Institute of Medicine 2011). Notable differences were one reviewer (YP) doing the extraction, with ongoing discussion with EGM about screening and extraction; these adaptations follow the updated guidance from the Patient-Centered Outcomes Research Institute (PCORI Methodology Committee 2013).
Search Strategy
A reference librarian was consulted on the bibliographic databases and search terms. To minimize publication bias, both published and gray literature such as conference papers, and working papers were searched via PubMed/MED-LINE, EconLit/EBSCO, Social Services Abstracts/ProQuest, PAIS International/ProQuest, Business Source Complete/EBSCO, PsycINFO, Scopus, Grey Literature Report by New York Academy of Medicine, the Kaiser Family Foundation, and the National Bureau of Economic Research. We searched for: (1) Medicare [Medicare] , (2) Part D [Part D, prescription drug, drug benefi*], and (3) drug utilization or out-of-pocket costs [use, utilization*, adherence*, non adherence*, compliance*, noncompliance*; cost*, spending*, expenditure*]. We combined three words, one per category (e.g., [Medicare] AND [Part D] AND [use] ). The last access date was November 7, 2015. Additional eligible studies were identified by hand searching of reference lists from primary articles and relevant reviews.
Review Process. Studies were eligible if they met prespecified exclusion and inclusion criteria. Exclusion criteria were intervention (non-Medicare Part D) and non-U.S. setting. Inclusion criteria were time horizon (published after 2010), English language, original research (not review articles or commentaries), population (eligible for Medicare Part D), presence of a comparison group, and outcomes (drug utilization or OOP costs). Eligibility was determined in two stages. First, titles, abstracts, and subject terms were screened for the exclusion criteria. Second, full text was reviewed for inclusion criteria. EndNote (version X7; Thomson Reuters, New York, NY, USA) was used to manage citations and full-text articles, and inclusion and exclusion criteria were tracked in Excel. Eligibility assessment was performed by YP and discussed with EGM.
Data Extraction
Study data were extracted by YP with results reviewed by EGM. The following information was extracted: research question, study design (data years, geographic location, population, treatment group, comparison group, time period, data sources, number of observations, and data analysis method), drug utilization, and OOP cost outcomes, and limitations. We did not do a metaanalysis because outcome measures vary across studies: drug utilization outcomes included pill-days per patient year, prescriptions per patient year, and different measures of cost-related nonadherence. The studies also varied with their comparison groups, time periods, health conditions, and analytic methods. For studies with similar outcomes, we qualitatively synthesize the findings and report the range of effect sizes.
Quality Assessment
We used predefined criteria and a fixed coding guide (see Appendix SA2) to systematically assess the risk of bias in each study. As the Institute of Medicine access (Chen, Rizzo, and Ortega 2011; Urmie et al. 2011) , and cost-related behavior changes such as medication cessation, applying to pharmaceutical assistance programs, and receiving free prescription samples (Urmie et al. 2011) . Table 1 summarizes these findings.
The strongest effect sizes were for medication use. For example, Nair et al. (2010) and Zimmer (2015) found a 17.5-20 percent increase in prescriptions, Briesacher et al. (2011) estimated that annual prescription fills per person increased from 1.8 to 3.4, and Kaestner and Nasreen (2012) observed a 30 percent increase in annual prescriptions. Increases were highest among beneficiaries receiving low-income subsidies (Yala et al. 2014 ). There were smaller effects for cost-related nonadherence. Urmie et al. (2011) observed that fewer participants stopped taking prescriptions due to cost (from 8.9 to 7.6 percent), applied for pharmaceutical manufacturer assistance (from 6.4 to 2.7 percent), or had limited prescription access (from 23.0 to 18.6 percent); yet two studies did not find statistically significant changes in delaying or foregoing prescriptions (Chen, Rizzo, and Ortega 2011) or cost-related problems in accessing prescription drugs (Chakravarty et al. 2015) .
Preconditions such as insurance types, coverage, and spending led to differential program impacts. Seniors newly gaining coverage or with improved coverage experienced reduced cost-related nonadherence (Safran et al. (2010) : from 26.0 to 19.4 percent; Kennedy et al. (2011) : from 22.1 to 14.3 percent). However, those who transitioned from employer-based prescription coverage to Part D plans with less generous coverage had increased costrelated nonadherence (OR = 1.7) (Safran et al. 2010) . Drug utilization increased most among beneficiaries whose benefits become more generous: seniors transitioning from generic-only to no-gap coverage had 106 more days supply than those experiencing a coverage decrease (Ettner et al. 2011 ). Higher users experienced disproportionate impacts: Those with the highest pre-Part D OOP drug spending experienced a 4.0 percent relative increase in drug utilization (Mott et al. 2010) .
Although studies consistently found increased drug utilization among the elderly, there were no observed pre/post-Part D differences between nonelderly Medicare beneficiaries with disabilities and nonelderly individuals ineligible for Medicare (incidence rate ratio = 0.877) (Nelson et al. 2014 ).
Impact of Medicare Part D on Specific Drug Utilization
Medicare Part D significantly increased drug utilization among patients taking medications for heart disease (Donohue et al. 2010; Zhang et al. 2011 ), (Fowler et al. 2013) , glaucoma (Blumberg et al. 2015) , coronary heart disease and/or diabetes mellitus (Hanlon 2013) , hyperlipidemia, hypertension, and/or diabetes (Zhang et al. 2010a ), kidney disease (Yusuf et al. 2014) , or with coronary stent placements . It also reduced cost-related nonadherence among beneficiaries with glaucoma (Blumberg et al. 2015) and with coronary stent placements . Table 2 summarizes these findings.
It is difficult to compare statistically the magnitude of these effects across diseases, as most studies restrict their populations to narrow disease groups. A notable exception is Zhang et al. (2010a) , who evaluated the impact of among those with hyperlipidemia, diabetes, and hypertension, finding that medication possession ratios improved the most among diabetics (17.9 percentage points). When comparing studies qualitatively, the most robust increase was observed in individuals with heart disease without prior drug coverage (Donohue et al. (2010): six more heart failure prescription annually; Zhang et al. (2011) : higher likelihood of antihypertensive utilization (OR = 1.4); Hanlon et al. (2013) : findings on antilipemic use consistent across race).
Although utilization increased for most disease-specific studies, some studies had mixed outcomes. Most studies found increased utilization of diabetes-related medications (Vaidya, Blazejewski, and Pinto (2012) : 55.1-61.3 percent increase in statin use; Gellad et al. (2013) : 2 to 3 times higher utilization of oral hypoglycemics, statins, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and brand-name insulin analogs). However, beneficiaries with cancer (Kircher et al. 2014 ) and depression (Lim, Jung, and Shi 2013) did not have significantly different drug utilization.
Impact of Donut Hole Coverage Gap on Drug Utilization
Medicare Part D coverage gaps negatively impacted drug utilization (see Table 3 ). Polinski et al. (2011) found that beneficiaries without financial assistance in the gap were more likely to discontinue (hazard ratio = 2.0). Compared to those with gap coverage, beneficiaries on plans without gap coverage had higher cost-related nonadherence regardless of whether they experienced the gap (OR = 5.75) or not (OR = 2.78) (Bakk 2015) .
Although the magnitude of the coverage gap impact varies across studies, investigators consistently showed that these gaps significantly limit the program's impact among patients with diabetes (Duru et al. 2010; Gu et al. 1696 HSR: Health Services Research 52:5 (October 2017) Joyce, Zissimopoulos, and Goldman 2013; Zissimopoulos et al. 2015) , cardiovascular disease (Hales and George 2010; Li et al. 2012; Polinski et al. 2012b; Stuart et al. 2013) , osteoporosis and arthritis (Conwell et al. 2011; Tamariz et al. 2011) , mental health , and kidney disease (Park et al. 2014) .
Although it is difficult to statistically compare effect sizes across studies that are limited to specific conditions, there is some evidence for lower utilization of cardiovascular drugs versus antidepressants in the coverage gap : antidepressant and heart failure drug utilization decreased by 5.0 and 9.4 percent, respectively; Zhang et al. [2012] : beneficiaries with multiple chronic conditions reduced their monthly use of antidepressants, heart failure drugs, and antidiabetics by 12.1, 12.9, and 13.4 percent, respectively).
The coverage gap prompted some substitution of generic for brand-name drugs. Beneficiaries who reached the gap decreased their brand-name medication use by 9.3 percent, but increased generic medication use by 7.4 percent (Nair et al. 2011) . Similarly, Zhang, Baik, and Lave (2013) found that beneficiaries without gap coverage or with generic-only gap coverage had fewer prescriptions filled per month, relative to the changes in the group with lowincome subsidy (16.0 percent and 10.8 percent reduction). Those with genericonly coverage had larger declines in brand-name drug utilization (8.2 percent vs. 6.7 percent decrease), while those without any coverage had larger declines in generic medication utilization (5.2 percent vs. 2.4 percent decrease).
The Impact of Benzodiazepine Exclusion on Drug Utilization and Inappropriate Medication Use
Benzodiazepines are excluded from Medicare Part D coverage, although some states offer supplemental coverage through Medicaid. Table 4 summarizes findings from benzodiazepine exclusion studies. The benzodiazepine exclusion led to a 10 percentage point reduction in utilization, while its utilization remained stable in states with partial and complete coverage through Medicaid (Briesacher et al. 2010) ; and elderly Medicare Advantage enrollees had larger decreases in benzodiazepine utilization than the near-elderly (Ong et al. 2012a,b) . Those losing benzodiazepine coverage when changing from private coverage to Medicare Part D increased their rates of fluid movement (switching on and off benzodiazepines; OR = 2.43), and switch patterns (substituting with other medications; OR = 2.09) (Chen and Kreling 2014) . Although these studies consistently found that the benzodiazepine exclusion decreased benzodiazepine utilization, Lai et al. (2015) explained that (2012) found that inappropriate drug utilization increased slightly among those moving from no coverage to Part D coverage (relative odds ratio = 1.3, p < .001). Similarly, Polinski et al. (2012a) projected that Medicare Part D implementation was associated with 5 percent increase in days' supply of antipsychotics. In contrast, Fu et al. (2010) found no significant difference in the likelihood of potentially inappropriate medication use between enrollees and nonenrollees.
Impact of Medicare Part D on Drug Utilization among Dual-eligibles
There is limited empirical evidence on Medicare Part D among dual-eligibles, summarized in Table 5 . There is some evidence that elderly dual-eligibles did not experience changes in pill-days, total number of prescriptions (Basu, Yin, and Alexander 2010) , or medication access (Domino and Farley 2010) . A qualitative study (Hensley 2012 ) of elderly dual-eligibles with mental illness reported that beneficiaries did not experience access problems during the transition and their needs for psychotropic and other medications were met. However, nonelderly disabled dual enrollees with mental illness experienced differential antipsychotic treatments depending on whether they lived in strict-cap (low limits on monthly fills) or no-cap states: post-Part D use of medications to treat schizophrenia (17.69 percent) and bipolar disorder (35.47 percent) increased disproportionately in strict-cap states (Madden et al. 2015) .
Out-of-Pocket Costs among the General Population
Most studies found that OOP costs among the general Medicare Part D population decreased, with estimates from $142 to $356 per person-year (Briesacher et al. 2011; Liu et al. 2011; Cheng and Rascati 2012; Kircher et al. 2014) or 20 percent (Zimmer 2015 ) (see Tables 1 and 2 ). These reductions in OOP costs were experienced across race/ethnicity (Mahmoudi and Jensen 2013) , although more for African Americans (Chen, Rizzo, and Ortega 2011) and nonelderly beneficiaries (b = À0.794) (Nelson et al. 2014) . This decline in OOP costs is supported by studies showing that beneficiaries with lowincome subsidies had even lower OOP costs (Yala et al. 2014; Yusuf et al. 2014; Yazdany, Tonner, and Schmajuk 2015) . Reductions in OOP costs grow consistently with baseline spending: Engelhardt and Gruber (2011) reported reductions of $180 at the median and $800 at the 90th percentile of baseline spending, and Mott et al. (2010) found that while seniors with lower pre-Part D spending had similar OOP costs, those with the highest pre-Part D spending had 17.6 percent fewer OOP costs. Yet not all studies documented reduced OOP costs: Nair et al. (2010) found that mean OOP expenditures increased from $45.66 to $81.83 per member per month, hypothesizing that this increase is due to the coverage gap when members paid 100 percent of medication costs. When looking at subgroups with different sources of prescription coverage, all Part D beneficiaries except those previously reporting employer-based coverage reported lower OOP spending, and Medicare Part D beneficiaries who previously lacked coverage experienced the largest reductions (Safran et al. 2010) . While annual OOP expenditures decreased by 32 percent ($320) for all Medicare beneficiaries, beneficiaries without previous drug coverage experienced a larger 49 percent decrease ($748) (Millett et al. 2010) . Similarly, beneficiaries whose prescription insurance become more generous, in terms of previous insurance caps (Zhang et al. 2010b; Ettner et al. 2011 ) and branded versus generic-only coverage (Ettner et al. 2011) , showed the highest reduction in OOP costs, with estimates of 15.9 percent (Zhang et al. 2010b) or around $200-300 (Ettner et al. 2011 ).
Out-of-Pocket Costs for Beneficiaries in Coverage Gap
Beneficiaries faced increased OOP expenditures in the gap (see Table 3 ). Nair et al. (2011) estimated an overall increase of 60.7 percent. These findings were consistent for beneficiaries with diabetes and osteoporosis. Fung et al. (2010) found that beneficiaries with diabetes had 189 percent higher OOP expenditures for all drugs compared to no-gap beneficiaries, and 14 percent higher OOP expenditures compared to those with generic-only gap coverage, and Conwell et al. (2011) found that OOP costs rose among teriparatide users enrolled in partial-or full-gap exposure plans (increases of 121 and 186 percent) but fell for those in no-gap exposure plans.
Impact of the Benzodiazepine Exclusion on Out-of-Pocket Costs
While several studies (Ong et al. 2012a,b) evaluated the benzodiazepine exclusion's impact on patients' deductibles, copayments, and plan reimbursements, only one study examined its effect on OOP costs (Polinski et al. 2012a ) (see Table 4 ). Polinski et al. (2012a) estimated a 37-62 percent decrease in OOP costs for antipsychotics among uninsured elderly patients newly obtaining drug insurance.
Out-of-Pocket Costs for Dual-Eligibles
Two quantitative studies (Basu, Yin, and Alexander 2010; Millett et al. 2010) and one qualitative study (Hensley 2012) found mixed outcomes or no significant changes in OOP costs among dual-eligibles (see Table 5 ). Compared to near-elderly patients with Medicaid coverage (Basu, Yin, and Alexander 2010) or elderly beneficiaries with previous coverage through Medicaid (Millett et al. 2010) , dual-eligibles did not have higher OOP costs. A qualitative study of adults with mental illness found mixed perceptions about the impact on OOP costs, with some interviewees expressing that Medicare Part D premiums and copayments were reasonable, while others revealing them to be a significant burden preventing them from obtaining other necessities (Hensley 2012) .
Quality Assessment
We scored 51, 35, and 14 percent of studies as high, medium, and low quality, respectively (see Data S1). The strongest study designs used nonequivalent controls with differences-in-differences regression models to compare differential trends between those becoming eligible for Medicare Part D to similar ineligible individuals (such as near-elderly, veterans, or with employer-sponsored drug coverage). Almost all studies using claims data had no attrition because they restricted to individuals continuously enrolled in the full year, while many survey-based studies had low response rates (e.g., Safran et al. 2010; Chakravarty et al. 2015) or else did not report rates of nonresponse. Across studies, there was minimal bias from the intervention affecting the data collection and quality. Studies using claims data commonly suffered from moderate measurement error, as prescription claims may not reflect actual use. Survey-based studies often had recall bias, particularly where respondents reported experiences in the past year. However, the Medical Expenditure Panel Survey, commonly used in these studies, minimizes recall bias by requesting that participants bring medications to interviews and verifying responses with pharmacies. Only 10 studies provided sufficient information to evaluate the risk of bias from missing data; among these studies we concluded that three had low bias along this dimension. Although most studies did not provide an extensive rationale for their choice of outcome measures and their validity/reliability, studies frequently used common measures (such as prescriptions per month, days of prescription filled, and OOP costs). Ten publications were linked studies reporting slightly different outcomes or patient populations; most notable was a study team analyzing administrative data from a large Pennsylvania health insurer (e.g., Donohue et al. 2010 Donohue et al. , 2011 Donohue et al. , 2012 . These studies had a rigorous design, were all graded as high quality, and provided incremental evidence, but the large number of linked studies in which the same data sources and study design were used for multiple manuscripts focusing on slightly different outcomes or drug classes limits external validity.
DISCUSSION
We systematically reviewed evidence on how Medicare Part D impacted OOP costs and drug utilization since the last 2010 systematic review. In addition to reviewing new studies, we focused on the coverage gap and Medicare Part D's effects on diverse subpopulations such as dual-eligibles and those with specific conditions. There is strong and robust evidence for increased drug utilization and decreased OOP costs across different medications, using a range of data sources and study designs. However, the generosity of beneficiaries' pre-Part D insurance and drug spending strongly moderated the program's impact. We also found that the benzodiazepine exclusion decreased drug utilization and OOP costs. These findings are consistent with those from the prior systematic review (Polinski et al. 2010) , although our findings demonstrate a longer term impact.
Despite the strong evidence for the overall effects of Medicare Part D and the coverage gap, there are three areas with weak evidence where further research is needed. First, there is limited research on how outcomes differ among dual-eligibles. This group was often deliberately excluded to reduce measurement error (such as procuring drugs from other coverage sources that are not available in the datasets) and internal validity (such as selection bias from individuals who transition across coverage sources). The few studies on this population found mixed outcomes, which could be due to the small and nonrepresentative samples (Millett et al. 2010; Hensley 2012) . Future research with representative samples is needed to evaluate effects on dual-eligibles with various health conditions and level of prescription drug spending. A second area with weak evidence is comparing findings across diseases or drug classes. With a few exceptions (Zhang et al. 2010a Baik et al. 2012) , most studies about specific conditions were restricted to narrowly defined clinical populations. Although these studies provide a deeper understanding of the impact of Medicare Part D, effect sizes cannot be statistically compared across studies. Future research comparing outcomes across diseases could elucidate whether some patient populations are more vulnerable to the coverage gap, thereby experiencing differential cost-related nonadherence. A third research gap is the long-term effect of Medicare Part D on drug utilization and OOP costs after the transition period.
There were some common study limitations that may have biased reported findings; yet with such a robust corpus of publications reporting similar effects using different study designs and data sources, we still conclude that there is a high-quality evidence for the overall effects of Medicare Part D on utilization and OOP costs. As this was a major policy change, there are no randomized controlled trials and all studies are observational. Most of the studies that we graded as high quality used a pre/post design with nonequivalent controls (such as near-elderly or individuals retaining employer-sponsored drug coverage) and a differences-in-differences framework. This analytic design should control for difference in groups as long as they have parallel trends in the prior to the policy intervention. However, as Stuart et al. (2013) noted, two sources of bias are that enrollees could have different OOP costs by changing their prescription filling behaviors, and there may be reverse causality because those with higher adherence will incur higher costs and thus be more likely to reach the gap. Many studies using this differences-in-difference design also did not explicitly test the parallel trends assumption. Second, a major source of measurement error with the 42 studies relying on claims data is that researchers cannot monitor whether beneficiaries consumed medications (actual vs. measured behavior) or whether beneficiaries received medications through other coverage sources such as pharmacy assistance programs. Claims data are also unable to provide information on reasons for reduced utilization; nonadherence (measured by fewer prescriptions) could be due to cost or else medical reasons such as side effects or the course of treatment ending (Chakravarty et al. 2015) . The survey-based studies can track drug use across insurance coverage sources and elicit reasons for nonadherence but are susceptible to other measurement error such as recall and nonresponse bias. Third, many studies have poor external validity because they use data from a single pharmacy chain or prescription plan, and limit analyses to individuals maintaining continuous enrollment. Finally, some of these studies may provide high quality evidence but were downgraded because we could only systematically evaluate the risk of bias based on the reported information. Information about missing data, attrition, and data collection procedures were commonly excluded. This highlights a broader need to clearly report study design, which researchers and medical journal editors are trying to improve through guidelines such as the Strengthening the Reporting of Observational Studies Statement (Vandenbroucke et al. 2007 ).
This systematic review has four limitations. Like all systematic reviews, it may suffer from the publication bias, which may overestimate effects. We could not compare results from published studies and gray literature as most gray literature meeting our inclusion criteria later became peer-reviewed articles and there was too much heterogeneity in study designs to do a statistical assessment. Second, the OOP cost savings represent the beneficiary, not societal perspective. Third, we did not review health outcomes, as most studies focused on utilization and OOP costs. Lastly, one reviewer (YP) identified studies and extracted data. This may lead to reviewer bias, although the new PCORI standards asserts that fact-checking may be sufficient (Hickam et al. 2013) and EGM was consulted on the study design and data synthesis.
More broadly, our findings can inform the potential impact of insurance market changes due to the Affordable Care Act (ACA). The ACA includes "essential health benefits," including drug benefits that plans must cover (HealthCare.gov, 2014) . Over 8 million people selected plans with prescription drug benefits through the federal or state exchanges (Office of the Assistant Secretary for Planning and Evaluation (ASPE) May 1, 2014). Our findings suggest that these essential benefits provisions may increase drug utilization and decrease OOP costs among those gaining new or improved coverage; however, these outcomes may worsen among those selecting less expensive high-deductible plans. A second relevant policy change is that Medicare beneficiaries in the donut hole now only pay 45 percent for brand-name drug and 58 percent for generic drugs and the gap will be closed by 2020 (The Official U.S. Government Site for Medicare 2016). We found that this coverage gap has a negative impact on beneficiaries; eliminating it will likely improve drug utilization, medication discontinuation, and OOP costs, especially to seniors with multiple conditions. To improve the ACA's impact, it is important to enroll those without previous insurance and minimize the crowding-out of less generous private insurance among those previously insured. Following our review's findings on the importance of the coverage gap, the closing of the gap provides an opportunity for future research to assess the population impact of this altered policy design.
